Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies DOI Open Access
Ali Zarrabi, David Perrin, Mahboubeh Kavoosi

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(21), P. 5269 - 5269

Published: Nov. 2, 2023

Rhabdomyosarcoma is a rare cancer arising in skeletal muscle that typically impacts children and young adults. It worldwide challenge child health as treatment outcomes for metastatic recurrent disease still pose major concern both basic clinical scientists. The strategies rhabdomyosarcoma include multi-agent chemotherapies after surgical resection with or without ionization radiotherapy. In this comprehensive review, we first provide detailed understanding of including its classification subtypes, diagnosis, strategies. Later, focus on chemotherapy childhood sarcoma discuss the impact three mechanisms are involved response apoptosis, macro-autophagy, unfolded protein response. Finally, vivo mouse zebrafish models vitro three-dimensional bioengineering to screen future therapeutic approaches promote regeneration.

Language: Английский

Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review DOI Creative Commons
Lukas Käsmann, Alexander Dietrich, Claudia A. Staab-Weijnitz

et al.

Radiation Oncology, Journal Year: 2020, Volume and Issue: 15(1)

Published: Sept. 10, 2020

Abstract Lung, breast, and esophageal cancer represent three common malignancies with high incidence mortality worldwide. The management of these tumors critically relies on radiotherapy as a major part multi-modality care, treatment-related toxicities, such radiation-induced pneumonitis and/or lung fibrosis, are important dose limiting factors direct impact patient outcomes quality life. In this review, we summarize the current understanding pulmonary present predictive well recent diagnostic therapeutic advances. Novel candidates for molecularly targeted approaches to prevent treat fibrosis discussed.

Language: Английский

Citations

175
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium DOI Creative Commons
Jack F. Shern, Joanna Selfe, Elisa Izquierdo

et al.

Journal of Clinical Oncology, Journal Year: 2021, Volume and Issue: 39(26), P. 2859 - 2871

Published: June 24, 2021

PURPOSE Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion status, no genomic markers are available risk stratification. We present an international consortium study designed to determine incidence driver mutations their association clinical outcome. PATIENTS AND METHODS Tumor samples collected from enrolled on Children's Oncology Group trials (1998-2017) UK malignant mesenchymal tumor RMS2005 (1995-2016) were subjected custom-capture sequencing. Mutations, indels, gene deletions, amplifications identified, analysis was performed. RESULTS DNA 641 suitable analyses. A median one mutation found per tumor. In FOXO1 fusion-negative cases, any RAS pathway member in > 50% 21% had putative identified. BCOR (15%), NF1 TP53 (13%) at a higher than previously reported associated worse outcomes both fusion-positive cases. Interestingly, isoforms predominated infants < 1 year (64% cases). Mutation MYOD1 histologic patterns those described, older age, head neck primary site, dismal survival. Finally, we provide searchable companion database ( ClinOmics ), containing all variants, annotation including data. CONCLUSION This largest characterization clinically annotated rhabdomyosarcoma tumors date provides prognostic genetic features that refine stratification will be incorporated into prospective trials.

Language: Английский

Citations

154
Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects DOI Open Access
Katie Hanna, Emma Krzoska, Abeer M. Shaaban

et al.

British Journal of Cancer, Journal Year: 2021, Volume and Issue: 126(8), P. 1125 - 1139

Published: Dec. 10, 2021

Language: Английский

Citations

122
Myocardial infarction detection based on deep neural network on imbalanced data DOI
Mohamed Hammad, Monagi H. Alkinani, Brij B. Gupta

et al.

Multimedia Systems, Journal Year: 2021, Volume and Issue: 28(4), P. 1373 - 1385

Published: Jan. 6, 2021

Language: Английский

Citations

118
Identification and functional characterization of transcriptional activators in human cells DOI Creative Commons
Nader Alerasool,

He Leng,

Zhen‐Yuan Lin

et al.

Molecular Cell, Journal Year: 2022, Volume and Issue: 82(3), P. 677 - 695.e7

Published: Jan. 10, 2022

Language: Английский

Citations

103
High-throughput single-сell sequencing in cancer research DOI Creative Commons
Qingzhu Jia, Han Chu, Jin Zheng

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: May 3, 2022

Abstract With advances in sequencing and instrument technology, bioinformatics analysis is being applied to batches of massive cells at single-cell resolution. High-throughput can be utilized for multi-omics characterization tumor cells, stromal or infiltrated immune evaluate progression, responses environmental perturbations, heterogeneous composition the microenvironment, complex intercellular interactions between these factors. Particularly, T cell receptors, alone combination with RNA sequencing, useful fields immunology immunotherapy. Clinical insights obtained from are critically important exploring biomarkers disease progression antitumor treatment, as well guiding precise clinical decision-making patients malignant tumors. In this review, we summarize applications evolution, immunology, Additionally, analyze response heterogeneity resistance checkpoint The limitations cancer research also discussed.

Language: Английский

Citations

99
Recent advances in multi-configurable nanomaterials for improved chemodynamic therapy DOI

Junya Lu,

Yuanqi Yang,

Qingqing Xu

et al.

Coordination Chemistry Reviews, Journal Year: 2022, Volume and Issue: 474, P. 214861 - 214861

Published: Oct. 1, 2022

Language: Английский

Citations

86
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials DOI
Josephine H. HaDuong, Christine M. Heske, Wendy Allen‐Rhoades

et al.

Pediatric Blood & Cancer, Journal Year: 2022, Volume and Issue: 69(4)

Published: Feb. 7, 2022

Children and adolescents with rhabdomyosarcoma (RMS) comprise a heterogeneous population variable overall survival rates ranging between approximately 6% 100% depending on defined risk factors. Although the stratification of patients has been refined across five decades collaborative group studies, molecular prognostic biomarkers beyond FOXO1 fusion status have yet to be incorporated prospectively in upfront risk-based therapy assignments. This review describes evolution current stratification, defines new incorporating novel biomarkers, provides rationale for upcoming Children's Oncology Group RMS studies.

Language: Английский

Citations

76
Next generation probiotics: Engineering live biotherapeutics DOI
Sanjeeva Kumar Murali, Thomas J. Mansell

Biotechnology Advances, Journal Year: 2024, Volume and Issue: 72, P. 108336 - 108336

Published: March 2, 2024

Language: Английский

Citations

31
Magnesium–ibogaine therapy in veterans with traumatic brain injuries DOI Creative Commons

Kirsten Cherian,

Jackob N. Keynan,

Lauren Anker

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(2), P. 373 - 381

Published: Jan. 5, 2024

Abstract Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, some to seek underexplored treatment alternatives the oneirogen ibogaine, plant-derived compound known interact with multiple neurotransmitter systems that has been studied primarily substance use disorders. Ibogaine associated instances fatal cardiac arrhythmia, but coadministration magnesium mitigate this concern. In present study, we report prospective observational study Magnesium–Ibogaine: Stanford Injury CNS protocol (MISTIC), provided together complementary modalities, in 30 male SOVs predominantly mild TBI. We assessed changes World Health Organization Disability Assessment Schedule from baseline immediately (primary outcome) 1 month (secondary after treatment. Additional secondary outcomes included PTSD (Clinician-Administered Scale DSM-5), (Montgomery–Åsberg Depression Rating Scale) anxiety (Hamilton Anxiety Scale). MISTIC resulted significant improvements functioning both ( P corrected < 0.001, Cohen’s d = 0.74) 2.20) 2.54), 2.80) 2.13) There were no unexpected or serious adverse events. Controlled clinical trials assess safety efficacy are needed validate initial open-label findings. ClinicalTrials.gov registration: NCT04313712 .

Language: Английский

Citations

19